Get AI intraday signals

GET DAILY SIGNALS

Emerson Electric (EMR, $67.18) gets rating boost from RBC, on breakup potential

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

EMR in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 01, 2026

EMR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 44 cases where EMR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 66%.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +2.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where EMR advanced for three days, in 211 of 340 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.

Bearish Trend Analysis

The 10-day RSI Indicator for EMR moved out of overbought territory on August 14, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 24 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 62%.

The Momentum Indicator moved below the 0 level on August 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EMR as a result. In 48 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 52%.

The Moving Average Convergence Divergence Histogram (MACD) for EMR turned negative on August 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 26 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 58%.

EMR moved below its 50-day moving average on September 14, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EMR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.

The Aroon Indicator for EMR entered a downward trend on September 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 34 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock slightly better than average.

The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.058) is normal, around the industry mean (5.205). P/E Ratio (32.451) is within average values for comparable stocks, (61.980). Projected Growth (PEG Ratio) (1.709) is also within normal values, averaging (1.833). Dividend Yield (0.015) settles around the average of (0.020) among similar stocks. P/S Ratio (4.484) is also within normal values, averaging (189.474).

The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. EMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 62 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.